Zydus and Formycon Secure FDA Acceptance for First Pembrolizumab Biosimilar

The FDA's acceptance of the first biosimilar BLA referencing pembrolizumab (Keytruda) signals that the regulatory pathway for PD-1 checkpoint inhibitor biosimilars is now open, a development biologics manufacturers and CMOs preparing for this space have been tracking closely. Zydus, holding exclusive commercialization rights for the United States and Canada, filed the application jointly with Formycon, a German biosimilar developer.

For QA directors and regulatory affairs leads, the acceptance marks a meaningful inflection point. Pembrolizumab is a high-complexity monoclonal antibody; demonstrating analytical and functional similarity to a molecule of this structural intricacy requires an extensive comparability package under 21 CFR Part 601 and ICH Q11 principles. The FDA's willingness to accept the filing for substantive review suggests the dossier met the threshold for analytical, nonclinical, and clinical data sufficiency, a bar that competing programs will now benchmark against.

Manufacturing complexity is the central operational variable here. Pembrolizumab biosimilars must match the reference product's critical quality attributes across glycosylation profile, binding affinity to PD-1, and Fc effector function, all of which are process-dependent and highly sensitive to upstream cell culture conditions and downstream purification steps. Biologics sites and contract manufacturers positioning for this wave of PD-1/PD-L1 biosimilar work will need robust process validation packages and comparability protocols aligned with current FDA expectations.

Zydus brings established commercial infrastructure in North America, which reduces the market-access execution risk typically associated with first-entry biosimilar launches. For the broader competitive landscape, acceptance of this BLA is likely to accelerate parallel filings from other sponsors who have been monitoring the regulatory posture around immuno-oncology biosimilars, a category that has lagged small-molecule generics in development timelines due to manufacturing and clinical complexity.

The PDUFA action date, once assigned, will set the clock for the FDA's formal review cycle and will be the next measurable checkpoint for manufacturers and regulatory teams tracking this program's progress toward potential approval.

Source: Media4Growth via Indian Pharma Post, 12 October 2026.